These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Advances in understanding the pathogenesis of familial myeloproliferative neoplasms. Rumi E; Cazzola M Br J Haematol; 2017 Sep; 178(5):689-698. PubMed ID: 28444727 [TBL] [Abstract][Full Text] [Related]
3. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients. Trifa AP; Bănescu C; Tevet M; Bojan A; Dima D; Urian L; Török-Vistai T; Popov VM; Zdrenghea M; Petrov L; Vasilache A; Murat M; Georgescu D; Popescu M; Pătrinoiu O; Balea M; Costache R; Coleș E; Șaguna C; Berbec N; Vlădăreanu AM; Mihăilă RG; Bumbea H; Cucuianu A; Popp RA Br J Haematol; 2016 Jul; 174(2):218-26. PubMed ID: 27061303 [TBL] [Abstract][Full Text] [Related]
4. Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms. Jäger R; Harutyunyan AS; Rumi E; Pietra D; Berg T; Olcaydu D; Houlston RS; Cazzola M; Kralovics R Am J Hematol; 2014 Dec; 89(12):1107-10. PubMed ID: 25196853 [TBL] [Abstract][Full Text] [Related]
5. Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms. Hinds DA; Barnholt KE; Mesa RA; Kiefer AK; Do CB; Eriksson N; Mountain JL; Francke U; Tung JY; Nguyen HM; Zhang H; Gojenola L; Zehnder JL; Gotlib J Blood; 2016 Aug; 128(8):1121-8. PubMed ID: 27365426 [TBL] [Abstract][Full Text] [Related]
6. JAK2 haplotype 46/1 and JAK2 V617F allele burden in MPN: New evidence against the "hypermutability" hypothesis? Stolyar MA; Klimova OA; Gorbenko AS; Brenner EV; Titov SE; Ivanov MK; Olkhovskiy IA Int J Lab Hematol; 2018 Feb; 40(1):e8-e10. PubMed ID: 29134760 [No Abstract] [Full Text] [Related]
7. Coexisting driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients. De Roeck L; Michaux L; Debackere K; Lierman E; Vandenberghe P; Devos T Hematology; 2018 Dec; 23(10):785-792. PubMed ID: 29993347 [TBL] [Abstract][Full Text] [Related]
8. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Kilpivaara O; Mukherjee S; Schram AM; Wadleigh M; Mullally A; Ebert BL; Bass A; Marubayashi S; Heguy A; Garcia-Manero G; Kantarjian H; Offit K; Stone RM; Gilliland DG; Klein RJ; Levine RL Nat Genet; 2009 Apr; 41(4):455-9. PubMed ID: 19287384 [TBL] [Abstract][Full Text] [Related]
10. Progenitor genotyping reveals a complex clonal architecture in a subset of CALR-mutated myeloproliferative neoplasms. Martin S; Wright CM; Scott LM Br J Haematol; 2017 Apr; 177(1):55-66. PubMed ID: 28168700 [TBL] [Abstract][Full Text] [Related]
11. MECOM, HBS1L-MYB, THRB-RARB, JAK2, and TERT polymorphisms defining the genetic predisposition to myeloproliferative neoplasms: A study on 939 patients. Trifa AP; Bănescu C; Bojan AS; Voina CM; Popa Ș; Vișan S; Ciubean AD; Tripon F; Dima D; Popov VM; Vesa ȘC; Andreescu M; Török-Vistai T; Mihăilă RG; Berbec N; Macarie I; Coliţă A; Iordache M; Cătană AC; Farcaș MF; Tomuleasa C; Vasile K; Truică C; Todincă A; Pop-Muntean L; Manolache R; Bumbea H; Vlădăreanu AM; Gaman M; Ciufu CM; Popp RA Am J Hematol; 2018 Jan; 93(1):100-106. PubMed ID: 29047144 [TBL] [Abstract][Full Text] [Related]
12. The JAK2 46/1 haplotype does not predispose to CALR-mutated myeloproliferative neoplasms. Soler G; Bernal-Vicente A; Antón AI; Torregrosa JM; Caparrós-Pérez E; Sánchez-Serrano I; Martínez-Pérez A; Sánchez-Vega B; Vicente V; Ferrer-Marin F Ann Hematol; 2015 May; 94(5):789-94. PubMed ID: 25482455 [TBL] [Abstract][Full Text] [Related]
13. Heterogeneity in myeloproliferative neoplasms: Causes and consequences. O'Sullivan J; Mead AJ Adv Biol Regul; 2019 Jan; 71():55-68. PubMed ID: 30528537 [TBL] [Abstract][Full Text] [Related]
14. Germline genetic factors in the pathogenesis of myeloproliferative neoplasms. Bellanné-Chantelot C; Rabadan Moraes G; Schmaltz-Panneau B; Marty C; Vainchenker W; Plo I Blood Rev; 2020 Jul; 42():100710. PubMed ID: 32532454 [TBL] [Abstract][Full Text] [Related]
15. JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapy. Ciboddo M; Mullally A Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):110-117. PubMed ID: 30504299 [TBL] [Abstract][Full Text] [Related]
17. Focus on the epigenome in the myeloproliferative neoplasms. Kim E; Abdel-Wahab O Hematology Am Soc Hematol Educ Program; 2013; 2013():538-44. PubMed ID: 24319229 [TBL] [Abstract][Full Text] [Related]
18. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond. Michiels JJ; Berneman Z; Schroyens W; De Raeve H Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092 [TBL] [Abstract][Full Text] [Related]